ATRA
Atara Biotherapeutics, Inc.
Overview
Atara Biotherapeutics, Inc is a Healthcare company operating in Biotechnology with a $90.7M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 10, 2026).
8 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q3 FY2023Earnings2023-11-0410 Q&A exchanges
- Q3 FY2022Earnings2022-11-0814 Q&A exchanges
- Q2 FY2022Earnings2022-08-0819 Q&A exchanges
- Q1 FY2022Earnings2022-05-0521 Q&A exchanges
- Q4 FY2021Earnings2022-02-2817 Q&A exchanges
- Q3 FY2021Earnings2021-11-0423 Q&A exchanges
- Q2 FY2021Earnings2021-08-0921 Q&A exchanges
- Q1 FY2021Earnings2021-05-0531 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-10EPS— vs $-0.35—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-10 | — | $-0.35 | — | — | — | — | EODHD |
Source: EODHD. ATRA reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks ATRA's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2023 | $3.43 | $4.45 | -22.9% | +6.4% | +3.6% |
| Q4 FY2023 | $3.63 | $4.39 | -17.4% | -3.4% | -5.7% |
| Q3 FY2023 | $3.56 | $4.43 | -19.6% | -1.3% | -2.4% |
| Q2 FY2023 | $3.20 | $4.37 | -26.7% | +5.1% | +5.7% |
| Q1 FY2022 | $3.37 | $4.48 | -24.8% | +1.6% | +3.0% |
| Q4 FY2022 | $3.00 | $4.47 | -32.8% | +5.2% | +5.2% |
| Q3 FY2022 | $3.07 | $4.38 | -29.9% | +1.6% | +0.5% |
| Q2 FY2022 | $3.52 | $4.43 | -20.5% | +0.2% | +2.1% |
| Q1 FY2021 | $3.16 | $4.62 | -31.6% | -2.9% | -2.0% |
| Q4 FY2021 | $3.57 | $4.65 | -23.2% | -0.2% | -2.7% |
Guidance change history
Sample- Q1 FY2023Lowered2023-04-15
- Q4 FY2023Lowered2023-13-15
- Q3 FY2023Lowered2023-10-15
- Q2 FY2023Lowered2023-07-15
- Q1 FY2022Lowered2022-04-15
- Q4 FY2022Lowered2022-13-15
- Q3 FY2022Lowered2022-10-15
- Q2 FY2022Lowered2022-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Anhco NguyenCEO1 yr 9 mono recorded callsCurrentSample
CEO since 2024 • 1/2 beats (50%) • last guidance raise Q3 FY2023
- Yanina Grant-huertaChief Accounting Officer1 yr 3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last guidance cut Q1 FY2023
- Pascal TouchonCEO0 mo6 callsFormerSample
CEO since 2024 • 1/2 beats (50%) • guidance suspended Q1 FY2023
- Eric J HyllengrenCFO4 mo8 callsFormerSample
CFO since 2024 • 1/2 beats (50%) • last guidance cut Q1 FY2023
- Jill HenrichEVP, Chief Regulatory Officer4 mono recorded callsFormerSample
OTHER_C_SUITE since 2024 • 1/2 beats (50%) • last call held guidance Q2 FY2023
- Amar MuruganEVP, Chief Legal Officer0 mono recorded callsFormerSample
OTHER_C_SUITE since 2024 • 1/2 beats (50%) • last guidance raise Q3 FY2023
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ATRA.
$ curl https://api.spokenalpha.com/v1/companies/ATRAFAQ
Frequently asked about ATRA
Where can I find Atara Biotherapeutics, Inc.'s (ATRA) earnings call transcripts?
Spoken Alpha indexes ATRA's earnings call transcripts at https://spokenalpha.com/companies/ATRA. Each call links to attributed speakers and parsed analyst Q&A. Atara Biotherapeutics, Inc.'s own investor relations page is at https://investors.atarabio.com/.
When was Atara Biotherapeutics, Inc.'s most recent earnings call?
Atara Biotherapeutics, Inc. (ATRA) held its most recent earnings call on 2023-11-04, covering fiscal Q3 2023.
What sector is ATRA in?
Atara Biotherapeutics, Inc. (ATRA) operates in the Healthcare sector (Biotechnology industry).